Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in moderate-to-severe atopic dermatitis
NCT04392154Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of lebrikizumab in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Started Jun 2020; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04392154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392154.